blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3160513

EP3160513 - SACCHARIDE DERIVATIVE OF A TOXIC PAYLOAD AND ANTIBODY CONJUGATES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.12.2020
Database last updated on 14.03.2026
FormerThe patent has been granted
Status updated on  10.01.2020
FormerGrant of patent is intended
Status updated on  08.09.2019
FormerExamination is in progress
Status updated on  27.07.2019
FormerGrant of patent is intended
Status updated on  21.03.2019
FormerExamination is in progress
Status updated on  07.09.2018
FormerRequest for examination was made
Status updated on  31.03.2017
FormerThe international publication has been made
Status updated on  31.01.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Glykos Finland Oy
Viikinkaari 6
00790 Helsinki / FI
[2017/18]
Inventor(s)01 / HELIN, Jari
Valurintie 66
05200 Rajamäki / FI
02 / SAARINEN, Juhani
Eljaksentie 3
00370 Helsinki / FI
03 / SATOMAA, Tero
Raetie 10 K
00700 Helsinki / FI
04 / EKHOLM, Filip S.
Veckjärventie 18 A
06150 Porvoo / FI
 [2020/07]
Former [2017/18]01 / HELIN, Jari
Valurintie 66
FI-05200 Rajamäki / FI
02 / SAARINEN, Juhani
Eljaksentie 3
FI-00370 Helsinki / FI
03 / SATOMAA, Tero
Raetie 10 K
FI-00700 Helsinki / FI
04 / EKHOLM, Filip S.
Veckjärventie 18 A
FI-06150 Porvoo / FI
Representative(s)Papula Oy
P.O. Box 981
00101 Helsinki / FI
[2017/18]
Application number, filing date15742047.226.06.2015
[2017/18]
WO2015FI50471
Priority number, dateFI2014000563430.06.2014         Original published format: FI 20145634
FI2014000606905.12.2014         Original published format: FI 20146069
FI2015000512023.02.2015         Original published format: FI 20155120
[2017/18]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016001485
Date:07.01.2016
Language:EN
[2016/01]
Type: A1 Application with search report 
No.:EP3160513
Date:03.05.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 07.01.2016 takes the place of the publication of the European patent application.
[2017/18]
Type: B1 Patent specification 
No.:EP3160513
Date:12.02.2020
Language:EN
[2020/07]
Search report(s)International search report - published on:EP07.01.2016
ClassificationIPC:A61K47/68, A61K47/54, A61P35/00, A61P35/02
[2019/13]
CPC:
A61K47/549 (EP,US); A61K47/6803 (EP,US); A61K47/68031 (EP,US);
A61K47/68033 (EP,US); A61K47/6809 (EP,US); A61K47/6829 (EP,US);
A61K47/6831 (EP,US); A61K47/6849 (EP,US); A61K47/6855 (EP,US);
A61P35/02 (EP,US) (-)
Former IPC [2017/18]A61K47/50, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/18]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:SACCHARIDDERIVAT EINER TOXISCHEN NUTZLAST UND ANTIKÖRPERKONJUGATE DAVON[2017/18]
English:SACCHARIDE DERIVATIVE OF A TOXIC PAYLOAD AND ANTIBODY CONJUGATES THEREOF[2017/18]
French:DÉRIVÉ DE SACCHARIDE D'UNE CHARGE UTILE TOXIQUE ET CONJUGUÉS D'ANTICORPS DE CELUI-CI[2017/18]
Entry into regional phase30.01.2017National basic fee paid 
30.01.2017Designation fee(s) paid 
30.01.2017Examination fee paid 
Examination procedure30.01.2017Examination requested  [2017/18]
30.01.2017Date on which the examining division has become responsible
17.08.2017Amendment by applicant (claims and/or description)
07.09.2018Despatch of a communication from the examining division (Time limit: M06)
30.01.2019Reply to a communication from the examining division
22.03.2019Communication of intention to grant the patent
24.07.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
09.09.2019Communication of intention to grant the patent
02.01.2020Fee for grant paid
02.01.2020Fee for publishing/printing paid
02.01.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20156566.0  / EP3682904
Opposition(s)13.11.2020No opposition filed within time limit [2021/03]
Fees paidRenewal fee
27.06.2017Renewal fee patent year 03
27.06.2018Renewal fee patent year 04
27.06.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.06.2015
AL12.02.2020
CY12.02.2020
CZ12.02.2020
EE12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
MK12.02.2020
MT12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
TR12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
LU26.06.2020
PT05.07.2020
[2022/31]
Former [2022/30]HU26.06.2015
AL12.02.2020
CY12.02.2020
CZ12.02.2020
EE12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
MT12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
TR12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
LU26.06.2020
PT05.07.2020
Former [2022/27]HU26.06.2015
CY12.02.2020
CZ12.02.2020
EE12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
MT12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
TR12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
LU26.06.2020
PT05.07.2020
Former [2021/15]CZ12.02.2020
EE12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
LU26.06.2020
PT05.07.2020
Former [2021/12]CZ12.02.2020
EE12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
MC12.02.2020
PL12.02.2020
RO12.02.2020
RS12.02.2020
SI12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2020/50]CZ12.02.2020
EE12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
RO12.02.2020
RS12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2020/49]CZ12.02.2020
HR12.02.2020
LT12.02.2020
LV12.02.2020
RO12.02.2020
RS12.02.2020
SK12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2020/48]HR12.02.2020
LT12.02.2020
LV12.02.2020
RO12.02.2020
RS12.02.2020
SM12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
PT05.07.2020
Former [2020/47]HR12.02.2020
LT12.02.2020
LV12.02.2020
RS12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
Former [2020/40]HR12.02.2020
LV12.02.2020
RS12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
IS12.06.2020
Former [2020/39]HR12.02.2020
LV12.02.2020
RS12.02.2020
BG12.05.2020
NO12.05.2020
GR13.05.2020
Former [2020/38]HR12.02.2020
LV12.02.2020
RS12.02.2020
NO12.05.2020
GR13.05.2020
Former [2020/37]HR12.02.2020
LV12.02.2020
RS12.02.2020
NO12.05.2020
Former [2020/35]NO12.05.2020
Cited inInternational search[ID] WO2014096551  (GLYKOS FINLAND OY et al.)
 [E] WO2015110935  (PFIZER et al.)
 [X]   FRIEND D R ET AL: "Drug glycosides: Potential prodrugs for colon-specific drug delivery", JOURNAL OF MEDICINAL CHEMISTRY 1985 US, vol. 28, no. 1, 1985, pages 51 - 57, XP002745534, ISSN: 0022-2623

DOI:   http://dx.doi.org/10.1021/jm00379a012
 [X]   TIETZE LUTZ F ET AL: "Synthesis and biological evaluation of prodrugs based on the natural antibiotic duocarmycin for use in ADEPT and PMT.", CHEMISTRY (WEINHEIM AN DER BERGSTRASSE, GERMANY) 7 FEB 2011, vol. 17, no. 6, 7 February 2011 (2011-02-07), pages 1922 - 1929, XP002745535, ISSN: 1521-3765

DOI:   http://dx.doi.org/10.1002/chem.201002798
 [X]   ZHANG G ET AL: "Syntheses and biological activities of disaccharide daunorubicins", JOURNAL OF MEDICINAL CHEMISTRY 20050811 US, vol. 48, no. 16, 11 August 2005 (2005-08-11), pages 5269 - 5278, XP002745536, ISSN: 0022-2623

DOI:   http://dx.doi.org/10.1021/jm050144u
 [X]   CHAO Z ET AL: "Development of an indirect competitive enzyme-linked immunosorbent assay (icELISA) using highly specific monoclonal antibody against paclitaxel", JOURNAL OF NATURAL MEDICINES 2013 SPRINGER JAPAN JPN, vol. 67, no. 3, July 2013 (2013-07-01), pages 512 - 518, XP002745537, ISSN: 1340-3443

DOI:   http://dx.doi.org/10.1021/jm050144u
 [A]   ZHAO P ET AL: "Amide N-Glycosylation by Asm25, an N-Glycosyltransferase of Ansamitocins", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 15, no. 8, 25 August 2008 (2008-08-25), pages 863 - 874, XP025533992, ISSN: 1074-5521, [retrieved on 20080822], DOI: 10.1016/J.CHEMBIOL.2008.06.007

DOI:   http://dx.doi.org/10.1016/j.chembiol.2008.06.007
by applicantUS5635483
 US13482605
 US2006074008
 US2006022925
 WO2014096551
 WO2014177771
 WO9734632
 WO9515769
 US2009274713
 US7091186
 US7553816
 US6214345
 US7090843
 US2004018194
 WO2011051484
 WO2011054837
 WO0183448
 WO2007011968
 WO2008083312
 WO2008074004
 WO2007089149
 DE4415463
 US7811572
 US6411163
 US7368565
 US8163888
 US2011003969
 US2011166319
 US2012253021
 US2012259100
 US2014288280
 US7837980
 US2004157782
 US2005238649
 US2004038392
 WO2014017771
 EP79300469
 US5208020
 US6441163
   DORONINA ET AL., BIOCONJUG. CHEM., vol. 17, no. 1, 2006, pages 114 - 24
   INT. J. ONCOL., vol. 15, 1999, pages 367 - 72
   MOL. CANCER THER., vol. 3, 2004, pages 921 - 32
   PETTIT, G.R. ET AL., J. NAT. PROD., vol. 74, 2011, pages 962 - 8
   DORONINA ET AL., BIOCONJ. CHEM., vol. 19, 2008, pages 1960 - 3
   DOSIO ET AL., TOXINS, vol. 3, 2011, pages 848 - 883
   SAMMET ET AL., PHARM. PAT. ANALYST, vol. 1, no. 1, 2012, pages 2046 - 8954
   CHEN J; YIN S; WU Y; OUYANG J: "Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody-drug conjugates", ANAL CHEM., vol. 85, no. 3, 5 February 2013 (2013-02-05), pages 1699 - 1704
   TROUT ET AL., 79 PROC. NATL. ACAD. SCI. USA, 1982, pages 626 - 629
   UMEMOTO ET AL., 43 INT. J. CANCER, 1989, pages 677 - 684
   SAITO ET AL., ADV. DRUG DELIV. REV., vol. 55, 2003, pages 199 - 215
   TRAIL ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, 2003, pages 328 - 337
   PAYNE, CANCER CELL, vol. 3, 2003, pages 207 - 212
   ALLEN, NAT. REV. CANCER, vol. 2, 2002, pages 750 - 763
   PASTAN; KREITMAN, CUFF. OPIN. INVESTIG. DRUGS, vol. 3, 2002, pages 1089 - 1091
   SENTER; SPRINGER, ADV. DRUG DELIV. REV., vol. 53, 2001, pages 247 - 264
   TRANOY-OPALINSKI ET AL.: "?-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update", EUR J MED CHEM., vol. 74, 2014, pages 302 - 313
   JEFFREY ET AL.: "Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates", BIOCONJUG CHEM., vol. 17, 2006, pages 831 - 840
   CHEN ET AL.: "Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue", MOL PHARM., vol. 10, 2013, pages 1773 - 1782
   TIETZE ET AL.: "Photoactivatable prodrugs of highly potent duocarmycin analogues for a selective cancer therapy", CHEMISTRY, vol. 19, 2013, pages 1726 - 1731
   TIETZE; SCHMUCK: "Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT", CURR PHARM DES., vol. 17, 2011, pages 3527 - 3547
   TIETZE ET AL.: "Synthesis and biological evaluation of prodrugs based on the natural antibiotic duocarmycin for use in ADEPT and PMT", CHEMISTRY, vol. 17, 2011, pages 1922 - 1929
   SEUBERT ET AL.: "Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a ?-galactosidase-activatable prodrug seco-analog of duocarmycin SA", CANCER GENE THER., vol. 18, 2011, pages 42 - 52
   TIETZE ET AL.: "Glycosidic prodrugs of highly potent bifunctional duocarmycin derivatives for selective treatment of cancer", ANGEW CHEM INT ED ENGL., vol. 49, 2010, pages 7336 - 7339
   SCHUSTER ET AL.: "Synthesis of the first spacer containing prodrug of a duocarmycin analogue and determination of its biological activity", ORG BIOMOL CHEM., vol. 8, 2010, pages 1833 - 1842
   TIETZE ET AL.: "Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065", TOXINS (BASEL, vol. 1, 2009, pages 134 - 150
   TIETZE; KREWER: "Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies", CHEM BIOL DRUG DES., vol. 74, 2009, pages 205 - 211
   TIETZE ET AL.: "Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer", INT J MOL SCI, vol. 9, 2008, pages 821 - 837
   TIETZE; KREWER: "Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies", ANTICANCER AGENTS MED CHEM, vol. 9, 2009, pages 304 - 325
   TIETZE ET AL.: "Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy", J MED CHEM., vol. 52, 2009, pages 537 - 543
   TIETZE ET AL.: "Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy", CHEM MED CHEM., vol. 3, 2008, pages 1946 - 1955
   TIETZE ET AL.: "Duocarmycin-based prodrugs for cancer prodrug monotherapy", BIOORG MED CHEM., vol. 16, 2008, pages 6312 - 6318
   TIETZE ET AL.: "Enantio- and diastereoselective synthesis of duocarmycine-based prodrugs for a selective treatment of cancer by epoxide opening", CHEMISTRY, vol. 14, 2008, pages 895 - 901
   TIETZE ET AL.: "Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins", CHEMISTRY, vol. 13, 2007, pages 4396 - 4409
   TIETZE ET AL.: "Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy", ANGEW CHEM INT ED ENGL, vol. 45, 2006, pages 6574 - 6577
   TIETZE ET AL.: "Investigation of reactivity and selectivity of DNA-alkylating duocarmycin analogues by high-resolution mass spectrometry", ANGEW CHEM INT ED ENGL., vol. 45, 2006, pages 6570 - 6574
   TIETZE; FEUERSTEIN: "Enzyme and proton-activated prodrugs for a selective cancer therapy", CURR PHARM DES, vol. 9, 2003, pages 2155 - 2175
   TIETZE ET AL.: "Proof of principle in the selective treatment of cancer by antibody-directed enzyme prodrug therapy: the development of a highly potent prodrug", ANGEW CHEM INT ED ENGL., vol. 41, 2002, pages 759 - 761
   TIETZE ET AL.: "Highly selective glycosylated prodrugs of cytostatic CC-1065 analogues for antibody-directed enzyme tumor therapy", CHEMBIOCHEM, vol. 2, 2001, pages 758 - 765
   TIETZE ET AL.: "A strategy for tumor-selective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs", BIOORG MED CHEM, vol. 9, 2001, pages 1929 - 1939
   TIETZE ET AL.: "Stereoselective synthesis of (1-alkoxyalkyl) alpha- and beta-D-glucopyranosiduronates (acetal-glucopyranosiduronates): a new approach to specific cytostatics for the treatment of cancer", CARBOHYDR RES., vol. 180, 1988, pages 253 - 262
   TIETZE ET AL.: "Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: a strategy for tumor-selective activation of cytocidal drugs", CANCER RES., vol. 49, 1989, pages 4179 - 4184
   TIETZE ET AL.: "Synthesis, biological evaluation, and live cell imaging of novel fluorescent duocarmycin analogs", CHEM BIODIVERS., vol. 9, 2012, pages 2559 - 2570
   TIETZE ET AL.: "Synthesis of Fluorescence-Labelled Glycosidic Prodrugs Based on the Cytotoxic Antibiotic Duocarmycin", EUR. J ORG CHEM, 2010, pages 6909 - 6921
   WIRTH ET AL.: "The Two Faces of Potent Antitumor Duocarmycin-Based Drugs: A Structural Dissection Reveals Disparate Motifs for DNA versus Aldehyde Dehydrogenase 1 Affinity", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 52, 2013, pages 6921 - 6925
   TIETZE ET AL.: "Synthesis and Biological Evaluation of Novel Analogues and Prodrugs of the Cytotoxic Antibiotic CC-1065 for Selective Cancer Therapy", EUR J ORG CHEM, 2002, pages 1634 - 1645
   TIETZE ET AL.: "Prodrugs of the Cytostatic CC-1065 That Can Be Activated in a Tumor-Selective Manner", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 35, 1996, pages 2674 - 2677
   ZHAO ET AL.: "Amide N-glycosylation by Asm25, an N-glycosyltransferase of ansamitocins", CHEM BIOL., vol. 15, 2008, pages 863 - 874
   LU ET AL.: "A novel amide N-glycoside of ansamitocins from Actinosynnema pretiosum", J ANTIBIOT (TOKYO, vol. 57, 2004, pages 348 - 350
   CARTER; SENTER, CANCER J, vol. 14, no. 3, 2008, pages 154
   STAHELIN; VON WARTBURG, CANCER RES., vol. 51, 1991, pages 5 - 15
   V. PERRON; S. ABBOTT; N. MOREAU; D. LEE; C. PENNEY; B. ZACHARIE, SYNTHESIS, 2009, pages 283 - 289
   A. SARKAR; S. R. ROY; N. PARIKH; A. K. CHAKRABORTI, J. ORG. CHEM., vol. 76, 2011, pages 7132 - 7140
   TIETZE ET AL., ANGEW. CHEM. INT. ED., vol. 49, 2010, pages 7336 - 9
   B. N. A. MBADUGHA; F. M. MENGER, ORG. LETT., vol. 5, 2003, pages 4041
   M. A. BRIMBLE; R. KOWALCZYK; P. W. R. HARRIS; P. R. DUNBAR; V. J. MUIR, ORG. BIOMOL. CHEM., vol. 6, 2008, pages 112
   ZHAO ET AL., CHEMISTRY & BIOLOGY, vol. 15, 2008, pages 863 - 74
   COHEN ET AL., CANCER RES, vol. 74, 2014, pages 5700 - 10
   VAN DER LEE ET AL., MOL. CANCER THER., vol. 14, 2015, pages 692 - 703
   MOLDENHAUER ET AL., J. NATL. CANCER INST., vol. 104, 2012, pages 622 - 34
   EISSLER ET AL., CHEM. EUR. J., vol. 15, 2009, pages 11273 - 87
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.